A Pilot Study of Pembrolizumab Combined With Stereotactic Ablative Radiotherapy for Patients With Advanced or Metastatic Sarcoma

A Pilot Study of Pembrolizumab Combined With Stereotactic Ablative Radiotherapy for Patients With Advanced or Metastatic Sarcoma

Objectives Immunotherapy with immune checkpoint inhibitors has shown only limited success in the management of metastatic soft tissue sarcoma. Overall response rates (ORR) with single agent pembrolizumab were 18% and median PFS was 18 weeks on the clinical trial SARC028. One strategy to improve the...

Full description

Bibliographic Details
Main Authors:	Jeremy P. Harris MD, MPhil, Jino Park MD, Eric Ku MD, Steven Seyedin MD, Russell Stitzlein MD, Amanda Goldin MD, Wen-Pin Chen MS, Christine McLaren PhD, Allen M. Chen MD, Warren Chow MD
Format:	Article
Language:	English
Published:	SAGE Publishing 2024-02-01
Series:	Cancer Control
Online Access:	https://doi.org/10.1177/10732748241237331

Similar Items

Adrenal oligometastasis cured with stereotactic ablative radiotherapy
by: Julia Malone, BSC, et al.
Published: (2020-11-01)

Radiation-Induced Peripheral Neuropathy After Thoracic Stereotactic Ablative Radiotherapy: Case Report
by: Ha H. Pham, MD, PhD, et al.
Published: (2022-08-01)

Lichen planopilaris associated with pembrolizumab in a patient with metastatic melanoma
by: Anna L. Cogen, MD, PhD, et al.
Published: (2018-03-01)

Recent Advances and Challenges in Stereotactic Body Radiotherapy
by: Atsuto Katano MD, PhD, et al.
Published: (2024-02-01)

Effect of Radiotherapy Dose on Outcome in Nonmetastatic Ewing Sarcoma
by: Josephine Kersting, et al.
Published: (2023-07-01)

Combination of Pembrolizumab and Stereotactic Body Radiation Therapy in Recurrent Metastatic Penile Squamous Cell Carcinoma: A Case Study
by: Dalia Kaakour, et al.
Published: (2022-11-01)

Stereotactic radiotherapy of radiation-induced meningioma previously irradiated retrobulbar for Graves' ophthalmopathy: A case report
by: Nao Tachizawa, MD, et al.
Published: (2024-03-01)

Stereotactic body radiotherapy for metastatic sarcoma to the lung: adding to the arsenal of local therapy
by: Paulina M. Gutkin, et al.
Published: (2023-03-01)

EUS-guided ethanol ablation of metastatic functional insulinoma
by: Ahmed Altonbary, MD, FRCP, et al.
Published: (2021-10-01)

Advances in Radiobiology of Stereotactic Ablative Radiotherapy
by: Bin Qiu, et al.
Published: (2020-08-01)

Tumor Lysis Syndrome in a Patient With Metastatic Endometrial Cancer Treated With Lattice Stereotactic Body Radiation Therapy
by: Joshua P. Schiff, MD, et al.
Published: (2022-01-01)

Metastatic pulmonary synovial sarcoma: A double coincidence: Case report
by: Khadija Laasri, MD, et al.
Published: (2023-03-01)

Surgical and Pathologic Outcomes of Pancreatic Adenocarcinoma (PA) After Preoperative Ablative Stereotactic Magnetic Resonance Image Guided Adaptive Radiation Therapy (A-SMART)
by: J.M. Bryant, MD, et al.
Published: (2022-11-01)

Impact of Stereotactic Body Radiotherapy on Thrombin Generation and Platelet Aggregation in Patients with Non-Small Cell Lung Cancer
by: Kristian Kirkelund Bentsen MD, et al.
Published: (2023-11-01)

Pembrolizumab-induced rash in a patient with angiosarcoma
by: Justin Qian, BA, et al.
Published: (2022-11-01)

Complete response of metastatic cutaneous squamous cell carcinoma and multiple locally advanced basal cell carcinomas with concomitant pembrolizumab and sonidegib therapy
by: Carlos González-Cruz, MD, et al.
Published: (2024-04-01)

Radiofrequency Ablation of Recurrent Metastatic Papillary Thyroid Cancer to a Lymph Node
by: Shahzad Ahmad, MD, et al.
Published: (2022-11-01)

Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC
by: Marina C. Garassino, MD, et al.
Published: (2023-01-01)

A Phase 1 Study of Concurrent Neoadjuvant Pembrolizumab Plus Chemoradiation Followed by Consolidation Pembrolizumab in Patients With Resectable Stage IIIA NSCLC
by: Christopher A. Lemmon, MD, et al.
Published: (2022-07-01)

A case of pelvic EWSR1-PATZ1 fusion sarcoma treated with carbon ion radiotherapy
by: Toshinari Yagi, MD, et al.
Published: (2024-07-01)

Pemetrexed and Platinum Plus Pembrolizumab in Patients With Metastatic Nonsquamous NSCLC by Tumor Burden at Baseline: A Post Hoc Efficacy Analysis of KEYNOTE-189
by: Shirish Gadgeel, MD, et al.
Published: (2022-11-01)

A framework for exactrac dynamic commissioning for stereotactic radiosurgery and stereotactic ablative radiotherapy
by: Ben Perrett, et al.
Published: (2022-01-01)

A case of pembrolizumab-induced pigmented purpuric dermatosis
by: Oluwaseun J. Oyeku, BS, et al.
Published: (2023-04-01)

Simultaneous Multiple Liver Metastasis Treated with Pencil Beam Proton Stereotactic Body Radiotherapy (SBRT)
by: Neil K. Taunk, MD, MSCTS, et al.
Published: (2021-04-01)

Stereotactic ablative radiotherapy for acquired resistance to EGFR therapy in metastatic non-small cell lung cancer
by: Rodolfo Chicas-Sett, et al.
Published: (2023-01-01)

Stereotactic ablative radiotherapy for primary renal cell carcinoma
by: Daniel X. Yang, et al.
Published: (2024-01-01)

Stereotactic body radiotherapy for recurrent and oligometastatic soft tissue sarcoma
by: Xiao-Yao Feng, et al.
Published: (2022-09-01)

Increase in right ventricular lead pacing threshold following stereotactic ablative therapy for ventricular tachycardia
by: Nadeev Wijesuriya, MBBS, et al.
Published: (2023-08-01)

Complete metabolic response after Partially Ablative Radiotherapy (PAR) for bulky retroperitoneal liposarcoma: A case report
by: Federica Medici, MD, et al.
Published: (2024-01-01)

Magnetic Resonance-Guided Stereotactic Body Radiation Therapy/Hypofractionated Radiation therapy for Metastatic and Primary Central and Ultracentral Lung Lesions
by: Maria L. Sandoval, MD, MS, et al.
Published: (2023-05-01)

Real-World Data Analysis of Pembrolizumab Monotherapy for NSCLC Using Japanese Postmarketing All-Case Surveillance Data
by: Hideki Terai, MD, et al.
Published: (2022-11-01)

Effect of Target Changes on Target Coverage and Dose to the Normal Brain in Fractionated Stereotactic Radiation Therapy for Metastatic Brain Tumors
by: Hideharu Miura, PhD, et al.
Published: (2023-11-01)

Stereotactic ablative body radiotherapy with a central high dose using CyberKnife for metastatic lung tumors
by: Kazuhiko Hayashi, et al.
Published: (2023-03-01)

Educational Case: Myeloid Sarcoma: A Subtype of Acute Myeloid Leukemia
by: Ananya Datta Mitra MD, et al.
Published: (2020-09-01)

Tolerance of Concurrent Adjuvant Radiation Therapy and Pembrolizumab for Triple Negative Breast Cancer: Real Life Experience
by: Thais Tison, MD, et al.
Published: (2024-03-01)

Causes of Death Among Patients With Initially Inoperable Pancreas Cancer After Induction Chemotherapy and Ablative 5-fraction Stereotactic Magnetic Resonance Image Guided Adaptive Radiation Therapy
by: Michael D. Chuong, MD, et al.
Published: (2023-01-01)

Primary intramedullary extradural Ewing sarcoma
by: Alameen Damer, MD, et al.
Published: (2024-06-01)

Fractionated stereotactic radiation therapy for intact brain metastases
by: Samuel R. Marcrom, MD, et al.
Published: (2017-10-01)

Simultaneous Presentation of Secondary Adrenal Insufficiency and Primary Hypothyroidism due to Pembrolizumab: A Case Report
by: Shivam Khatri BS, et al.
Published: (2023-08-01)

Ablation technologies
by: Onuralp Ergun, MD, et al.
Published: (2022-10-01)